Abstract
Asn-linked glycosylation is the most ubiquitous posttranslational protein modification in eukaryotes and archaea, and in some eubacteria. Oligosaccharyltransferase (OST) catalyzes the transfer of preassembled oligosaccharides on lipid carriers onto asparagine residues in polypeptide chains. Inefficient oligosaccharide transfer results in glycoprotein heterogeneity, which is particularly bothersome in pharmaceutical glycoprotein production. Amino acid variation at the X position of the Asn-X-Ser/Thr sequon is known to modulate the glycosylation efficiency. The best amino acid at X is valine, for an archaeal Pyrococcus furiosus OST. We performed a systematic alanine mutagenesis study of the archaeal OST to identify the essential and dispensable amino acid residues in the three catalytic motifs. We then investigated the effects of the dispensable mutations on the amino acid preference in the N-glycosylation sequon. One residue position was found to selectively affect the amino acid preference at the X position. This residue is located within the recently identified DXXKXXX(M/I) motif, suggesting the involvement of this motif in N-glycosylation sequon recognition. In applications, mutations at this position may facilitate the design of OST variants adapted to particular N-glycosylation sites to reduce the heterogeneity of glycan occupancy. In fact, a mutation at this position led to 9-fold higher activity relative to the wild-type enzyme, toward a peptide containing arginine at X in place of valine. This mutational approach is potentially applicable to eukaryotic and eubacterial OSTs for the production of homogenous glycoproteins in engineered mammalian and Escherichia coli cells.
Keywords: Enzyme Catalysis, Enzyme Mutation, Glycoprotein, Glycosylation, Membrane Enzymes, Asn-X-Ser/Thr, N-glycosylation, Glycoprotein Production, Macroheterogeneity, Oligosaccharyltransferase
Introduction
N-linked glycosylation is the most ubiquitous posttranslational protein modification in eukaryotes and archaea, and in some eubacteria (1–4). It plays an important role in determining the biological activities of glycoproteins as well as the medicinal efficacy of many pharmaceutical recombinant glycoproteins. The covalent attachment of an oligosaccharide occurs on the side chain of an asparagine residue in a polypeptide chain, within the Asn-X-Ser and Asn-X-Thr sequences, where X is any amino acid except for proline (5, 6). About one-third of the potential N-glycosylation sequons are not glycosylated in extracellular proteins (7–9). This fact indicates that the presence of a consensus sequence is essential but not sufficient for N-glycosylation. The percentage of proteins modified at a particular sequon is referred to as “site occupancy.” A recent comprehensive proteome analysis of mouse tissues and blood plasma revealed that more than 98% of N-linked glycosylated peptides derived from glycoproteins were not found in their unmodified form, indicating the high occupancy of N-glycosylation sites (10). Thus, for most N-glycosylation sequons in vivo, the N-glycan attachment is robust, resulting in a homogeneously glycosylated (100% occupancy) or unglycosylated (0% occupancy) site.
In contrast, for some recombinant glycoproteins produced in cultured cells, the N-glycan attachment is variable, resulting in a mixture of various glycoforms, including fully, partially, and unglycosylated protein species (11). This variation in glycan occupancy is referred to as “macroheterogeneity.” Because the glycan attachment enhances solubility, improves folding, facilitates secretion, and increases the in vivo half-life of glycoproteins, glycosylation isoforms of pharmaceutical glycoproteins, such as Antithrombin III and tissue-type plasminogen activator, have different medicinal efficacies within humans (12, 13). Therefore, controlling the macroheterogeneity of recombinant glycoproteins is vital in therapeutic glycoprotein production.
Oligosaccharyltransferase (OST)2 catalyzes the transfer of preassembled oligosaccharides on lipid carriers (lipid-linked oligosaccharides (LLO)) onto asparagine residues in polypeptide chains. The site occupancy is determined by the action of OST in eukaryotic cells. Although little information is available, the situation is probably similar in prokaryotic cells. Thus, the critical factors that affect the site occupancy are the supply of the oligosaccharide donors (LLO), the properties of the polypeptide acceptors, and the activity of the OST enzyme. First, in cultured cells overexpressing a recombinant glycoprotein, the limited supply of LLO induces variable site occupancy. The addition of exogenous intermediate substances is expected to increase the level of N-glycosylation, but it is not always effective because of the complexity of the biosynthetic pathway of LLO (11). Second, the manipulation of the amino acid sequence within a sequon and its flanking residues could improve the efficiency of N-glycosylation. The Asn-X-Thr sequon is always a better acceptor than the Asn-X-Ser sequon (13–15). The amino acid at the X position and those at the other positions adjacent to the sequon also influence the glycosylation efficiency (14–19). Thus, changing the amino acid sequence within and near the N-glycosylation site generating macroheterogeneity is a simple solution, but the outcome is not always predictable because the conformational factors around the sequon also influence the extent of N-glycosylation. The last method involves the custom-tailoring of an OST enzyme by mutagenesis. This provides an ideal solution for a specified target protein without manipulation of its amino acid sequence.
Oligosaccharyltransferase is a multisubunit membrane protein complex in higher eukaryotes (2) but a single-subunit membrane protein in lower eukaryotes, archaea, and eubacteria (20–22). The catalytic subunit of the OST enzymes has a common ancestor but is referred to differently among the three domains of life, as STT3 in eukaryotes, AglB in archaea, and PglB in eubacteria. The primary sequences (600 to 1000 residues) of the STT3/AglB/PglB proteins share a common architecture (23, 24). There is a multispan transmembrane region in the N-terminal half of the primary sequence, and the C-terminal half forms a globular domain (Fig. 1).
FIGURE 1.
Structure of the P. furiosus OST/AglB protein and positions of the mutated residues. The predicted membrane topology of the N-terminal transmembrane region and the crystal structure (2ZAG and 2ZAI) of the C-terminal globular domain of the P. furiosus AglB are shown. The predicted positions of the DXD motif and Asp-167 are indicated by yellow stars. The Asp-167 residue belongs to another previously unrecognized diacidic motif, GXXDX(D/E) (supplemental Fig. S4). The mutated amino acid residues are shown with the side chains in the close-up view of the active site of the OST/AglB protein. WWDYG motif, yellow; DK motif, green; other residues on the long, kinked helix, orange.
The sequence alignment of the STT3/AglB/PglB protein family members revealed two conserved motifs. A five-residue motif, WWDYG, resides in the C-terminal globular domain, whereas a diacidic motif, DXD or EXD (X denotes any amino acid residue), is found in the first lumenal/extracellular loop of the N-terminal transmembrane region. Mutagenesis studies demonstrated the essential roles of these two motifs in the OST activity of the STT3s from yeast and Leishmania major and PglB from Campylobacter jejuni (21, 25–29). In addition to the two motifs, the structure-based sequence alignment revealed a third conserved motif (21). The third motif was classified into three groups, according to the different consensus patterns, DXXKXXX(M/I), DXXMXXX(K/I), and MXXIXXX(I/V/W), which were named DK, DM, and MI, respectively (27). Eukaryotic STT3 proteins exclusively contain the DK motif, whereas eubacterial PglB proteins only contain the MI motif. In contrast, archaeal AglB proteins contain either the DK, DM, or MI motif. In vivo mutagenesis studies of the STT3 proteins from yeast and L. major revealed the requirement of the DK motif for survival (21, 28). An in vitro mutagenesis study of the C. jejuni PglB protein also confirmed the involvement of the MI motif in the activity (27).
We developed an in vitro OST assay using recombinant AglB expressed in Escherichia coli membrane fractions. The AglB protein from a hyperthermophilic archaeon, Pyrococcus furiosus, was used to perform a systematic mutagenesis study. We identified a residue position where amino acid replacement induced specific changes in the amino acid preference at the X position of the Asn-X-Thr sequon in peptide substrates. This study highlights the feasibility of creating a single point mutation in OST to optimize its activity toward a given N-glycosylation sequon, which would eventually lead to reduced macroheterogeneity in recombinant glycoproteins.
EXPERIMENTAL PROCEDURES
Preparation of the E. coli Membrane Fractions Containing the Full-length P. furiosus AglB
The DNA sequence of P. furiosus AglB (residues 1–967, PF0156, Q8U4D2_PYRFU) was amplified by PCR from genomic DNA using the primers 5′-GCAACTATCCATGGTGAAAACCCAAATAAAGGAG-3′ (NcoI underlined) and 5′-CTCGGATCCTTAATGATGATGATGGTGATGAGGAGCCGATGCAC-3′ (BamHI underlined). The PCR product was digested with NcoI and BamHI and cloned into pET-15b (Novagen) for expression in E. coli cells, with a C-terminal His6 tag. The C-terminal His-His in the original sequence of the P. furiosus AglB was used as part of the His6 tag. Single point mutant variants were generated using the QuikChange mutagenesis kit (Stratagene). The P. furiosus AglB and its variants were expressed in the E. coli C43(DE3) strain (Lucigen). The transformed E. coli cells were grown at 310 K in LB medium, supplemented with 50 mg l−1 ampicillin. When the A600 reached 0.6, isopropyl 1-thio-β-d-galactopyranoside was added to a final concentration of 0.5 mm. After a 4-h induction at 310 K, the cells were harvested by centrifugation. The cell pellets from a 200-ml LB culture were resuspended in 7.5 ml of 50 mm Tris-HCl buffer (pH 7.4) containing 150 mm NaCl, 2 mm MgCl2, and 1 mm PMSF, supplemented with complete protease inhibitor mixture (Roche) according to the manufacturer's instructions. After cell disruption by sonication, the lysate was centrifuged at 5700 × g for 10 min. The supernatant was ultracentrifuged using a Beckman Coulter Optima TLX ultracentrifuge equipped with a TLA 110 rotor at 100,000 × g at 4 °C for 1 h. The supernatant was discarded and the pellets were stored at −80 °C until use. Each pellet was dissolved in solubilization buffer (20 mm Tris-HCl (pH 7.4), 150 mm NaCl, 1% n-dodecyl-β-d-maltoside) and incubated for 1 h at ambient temperature. After ultracentrifugation at 100,000 × g, the supernatant was recovered and mixed with nickel-Sepharose high-performance resin (GE Healthcare) equilibrated with the solubilization buffer. The bound proteins were eluted with 300 mm imidazole and pooled for the OST assay. The amount of the AglB protein was quantified by SDS-PAGE and Western blotting, with rabbit polyclonal antibodies raised against the soluble domain of P. furiosus AglB and goat anti-rabbit IgG antibodies labeled with a fluorescent IRDye, 800CW (LI-COR). The fluorescence images were recorded with an Odyssey infrared imaging system (LI-COR) and were quantified using the Odyssey software V3.0.
Peptide Synthesis
The details of the peptide library and fluorescence labeling were described previously (14). The peptide concentrations were determined by the absorbance at 555 nm, with an extinction coefficient of 90,000 m−1 cm−1. The two peptides used in the OST assay were custom-synthesized (Hayashi Kasei, Osaka, Japan). The N-terminal carboxytetramethylrhodamine (TAMRA) was introduced during the peptide synthesis.
Oligosaccharyltransferase Assay
The OST assay was performed by the PAGE method (30). A 2-μl aliquot of crude LLO, prepared from P. furiosus cells as described previously (21), was transferred to a plastic tube and dried in a SpeedVac concentrator. Eight microliters of buffer (50 mm Tris-HCl (pH 7.5) containing 1 mm DTT, 10 mm MnCl2, 0.02% Tween 20) were added, and the assay tube was sonicated in a bath-type sonicator (120 W) for 5 min. One microliter of 30 μm TAMRA-peptide solution and 3 μl of the E. coli membrane fraction containing the full-length AglB or its mutants was added. The reaction mixture (total 12 μl) was incubated at 65 °C for 1 h. The reaction was stopped by adding 2.4 μl of 5× SDS sample buffer and heating at 95 °C for 1 min. The fluorescence images of the SDS-PAGE gel were recorded with an LAS-3000 multicolor image analyzer (Fuji Photo Film) and were quantified using the ImageGauge software (Fuji Photo Film). The relative acceptor efficiency of an individual sequon in the peptide library experiments is defined as the ratio of the amount of each glycopeptide to the total amount of the 19 glycopeptides. The changes in the amino acid preferences of the OST mutants were evaluated by a correlation analysis between the relative acceptor efficiencies of the wild-type AglB and its mutants.
RESULTS
Overexpression and Purification of Recombinant AglB
The DNA encoding the full-length AglB gene was amplified from P. furiosus genomic DNA and cloned into the vector pET15b with a C-terminal His tag. The protein was expressed in the membrane fraction of E. coli cells, solubilized with 1% n-dodecyl-β-d-maltoside, and purified by nickel affinity chromatography. To measure the amount of the AglB protein, we performed Western blotting and infrared imaging with fluorescently labeled secondary antibodies (supplemental Fig. S1). The details of the experimental results are provided under “Supplemental Information.”
In Vitro Mutagenesis Study of the Three Catalytic Motifs
To address the role of the three conserved motifs, WWDYG, DXD, and DK, alanine-scanning mutagenesis was performed. The positions of the mutations in the tertiary structure are shown in Fig. 1. All of the mutant proteins were expressed at levels similar to that of the wild-type protein (supplemental Fig. S1D). The oligosaccharyltransferase activity was measured in the presence of the LLO prepared from P. furiosus cells as the oligosaccharide donor and a synthetic eight-residue peptide containing the N-glycosylation consensus as the oligosaccharide acceptor (Fig. 2A). The peptide consists of the optimized amino acid sequence (14) and contains a fluorescent dye at the N terminus. The generated glycopeptides were separated from the unmodified peptides by SDS-PAGE and quantified by fluorescence imaging (30). The specific activity was defined as the amount of glycopeptide formed (fmol) per hour per unit amount of protein defined by infrared imaging (see details in supplemental Fig. S2).
FIGURE 2.
Effects of the alanine mutations on the oligosaccharyltransferase activity. A, schematic representation of the oligosaccharyltransferase activity assay. The OST enzyme requires an LLO as the donor and an oligopeptide containing the N-glycosylation sequon as the acceptor. The P. furiosus LLO is predicted to be a dolichol-pyrophosphate-linked glycan. Hexagons, P. furiosus N-glycan consisting of seven monosaccharide residues (21); circles, pyrophosphate group; rectangles, dolichol; φ, TAMRA dye. The glycopeptide product was separated from the unmodified peptide by SDS-PAGE and quantified by fluorescence imaging. B, alanine mutants in the DXD motif, at Asp-167, in the WWDYG motif, and within and near the DK motif. The alanine residue in the wild-type sequence was replaced by a glycine residue. The peptide substrate TAMRA-Ala-Pro-Tyr-Asn-Val-Thr-Lys-Arg contained the optimized sequence for P. furiosus AglB (14). The specific OST activity of the wild-type AglB was defined as 1. Data were compared with the wild type by an unpaired two-tailed t test, assuming unequal variance. *, p < 0.01; §, p < 0.05. The error bars represent the mean ± S.D. of three independent experiments.
The substitution of each aspartate residue in the DXD and WWDYG motifs led to a nearly complete loss of the activity (Fig. 2B). The substitution of each of the tryptophan residues in the WWDYG motif also impaired the enzymatic activity. The mutations of the tyrosine and glycine in the WWDYG motif had an inhibitory effect. The mutations of the three signature residues in the DK motif, Asp-571, Lys-574, and Ile-578, also had an inhibitory effect on the OST activity. These results confirmed the vital contribution of the three conserved motifs to the catalytic function of the archaeal OST.
Point Mutation at Position 574 Affects the Amino Acid Preference for the X Position of the Glycosylation Sequon
We compared the substrate specificity of the mutant AglBs with that of the wild-type AglB by examining the amino acid preference at the X position of the Asn-X-Thr sequon in the peptide substrates. We prepared a peptide library, sharing a common sequence, Cys-Arg-Gly-Asn-X-Thr-Ala-Arg (14). A fluorescent dye was appended to the side chain of the N-terminal cysteine for detection and quantification. The relative acceptor efficiency of different N-glycosylation sequences was determined for the wild-type enzyme (Fig. 3A). There were wide variations in the preference among the amino acids at X. A sequon containing proline was inactive, whereas a sequon with valine served as the most favored substrate. The same peptide library experiment was performed using the G515A mutant for comparison, and we found a similar tendency in the relative amino acid preference. In fact, the correlation plot between the wild-type enzyme and the G515A mutant shows a good linear relationship (Fig. 3A), although the G515A mutation caused a 40% reduction in the specific activity (Fig. 2B). We then tested nine other mutations that were dispensable for the OST activity. Among them, only the K574A mutant changed the amino acid preference significantly (Fig. 3B). A closer look at the correlation plot revealed that the mutation-induced changes in the preference were selective to arginine, lysine, and glutamate residues at the X position (Fig. 3C). The correlation plots for the other mutants are provided in supplemental Fig. S3.
FIGURE 3.
Comparison of the amino acid preference at the X position of the N-glycosylation sequon between the wild-type AglB and single point mutants. A, the peptide library consisted of 19 amino acids (no cysteine) at the X position of the N-glycosylation sequon Asn-X-Thr. C-TAMRA denotes the coupling of TAMRA-maleimide to the thiol group of the N-terminal cysteine residue. Duplicate assays for the same peptides containing the Asn-Ala-Thr sequon provided an error estimation of ± 10%. The correlation plot between the relative acceptor efficiencies of the wild-type enzyme and the G515A mutant indicates almost identical amino acid preference at X. B, R2 (squared correlation coefficient) values of the correlation plot between the acceptor peptide library experiments using the wild-type AglB and its mutants. The mutations investigated had little impact on the amino acid preferences at the X position, except for K574A. C, correlation plot between the wild-type AglB and the K574A mutant. The amino acid preferences toward arginine, lysine, and glutamate residues were selectively changed by the mutation.
We then substituted Lys-574 with six different amino acids other than alanine. The effects on the amino acid preference at the X position were similar to the K574A mutants (Fig. 4): increased efficiency for arginine and lysine and decreased efficiency for glutamate. The enhanced efficiency for arginine at the X position suggests that the K574 mutants may have a higher activity than the wild-type enzyme toward peptides containing the Asn-Arg-Thr sequon. As expected, four mutants had a higher activity on the Asn-Arg-Thr sequon than the wild-type enzyme (Fig. 5B). In contrast, all mutants had a lower specific activity than the wild type on the original Asn-Val-Thr sequon (Fig. 5A).
FIGURE 4.
Comparison of the amino acid preference at the X position of the N-glycosylation sequon between the wild-type AglB and the point mutations at position 574 to various amino acids. A, the correlation plots show that all of the mutations had similar impacts on the amino acid preferences at the X position, i.e. improved efficiency for arginine and lysine and decreased efficiency for glutamate. B, the R2 (squared correlation coefficient) values of the correlations were calculated before and after the omission of the marked amino acids. For example, R2 is 0.504 for the K574A mutant, and it increased to 0.935 when the arginine, lysine, and glutamate were excluded from the calculation (as indicated by -RKE).
FIGURE 5.
P. furiosus OST was adapted for a non-optimal N-glycosylation sequon by the point mutations at position 574. A, the specific OST activities of the point mutants at position 574 were compared. The peptide sequence was the same as that used in Fig. 2. B, the same assay was performed using a different peptide with arginine at the X position in place of valine. The activity of the wild-type AglB was defined as 1. Data were compared with the wild type by an unpaired two-tailed t test, assuming unequal variance. *, p < 0.01; §, p < 0.05. The error bars represent the mean ± S.D. of three independent experiments.
DISCUSSION
Mutagenesis Study of P. furiosus AglB
The sequence homology suggests that three conserved motifs are required for the OST activity. This expectation has been proven right for the eukaryotic STT3s and the eubacterial PglB by mutagenesis studies (21, 25–29). Here, we verified the contribution of these motifs to the OST activity of an archaeal AglB protein. We set up an in vitro OST assay using P. furiosus AglB expressed in the membrane fractions of E. coli cells (supplemental Figs. S1 and S2). The detection of the OST activity using the heterologously expressed AglB confirmed that the AglB protein is solely responsible for the OST activity and that neither posttranslational modifications nor other additional subunits are necessary for the OST activity. This finding guarantees the future installation of the P. furiosus AglB into artificial N-glycosylation machinery engineered in E. coli.
The almost complete loss of the OST activity by the mutations in the DXD and WWDYG motifs confirmed the essential roles in the archaeal OST activity (Fig. 2B). The alanine mutation of Asp-167 also impaired the OST activity (Fig. 2B). The Asp-167 residue belongs to another previously unrecognized diacidic motif, GXXDX(D/E) (supplemental Fig. S4). In good agreement, the alanine mutations in the corresponding region (G163SYDNE168) in yeast STT3 generated a lethal phenotype (31). Each alanine mutation of the three residues that define the DK motif reduced the OST activity, whereas the other mutations, except for Tyr-568 and Phe-575, within and flanking the DK motif retained nearly full activity (Fig. 2B). The results are in good accordance with the three-dimensional structure of the AglB protein. The three signature residues face the same side of the kinked helix, and the side chains are in close proximity to the essential WWDYG motif (Fig. 1).
Lysine 574 Is Located in the Proximity of the Amino Acid Residue at the X Position of the Asn-X-Thr Sequon
The K574A mutant exerted significant effects on the amino acid preference at the X position of the Asn-X-Thr sequon (Fig. 3C). These effects were position-specific, as the other residue positions in the WWDYG motif and the DK motif had little influence on the amino acid preference at X (Fig. 3B and supplemental Fig. S3). The effect of the K574A mutation resulted in an enhanced preference for arginine and lysine, a reduced preference for glutamate, and a similar preference for the other residues (Fig. 3C). Other mutations at residue 574 also affected the amino acid preference at X in a similar manner (Fig. 4). The interpretation of the effects of the K574 mutations appears to be rather simple. The removal of the positive charge by the replacement of Lys-574 relieves the arginine and lysine at the X position from the unfavorable electrostatic interactions and abolishes the electrostatic stabilization with the glutamate at the X position. In contrast, the effects of the size and shape of the side chain of residue 574 seem to be negligible. Indeed, the mutations to tryptophan and glycine had the same tendency on the amino acid preference. This indicates that the influence of the lysine at residue 574 basically occurs via long-range electrostatic interactions.
Spatial Arrangement of the Putative Catalytic Site
The spatial arrangement of the two substrates, LLO and the Asn-X-Thr sequon, in the catalytic site is summarized in Fig. 6. Three interactions (denoted by i, ii, and iii) are formed, at least transiently, with the catalytic motifs of AglB during the sequon recognition and the subsequent reaction. Residue 574 corresponds to the second signature residue of the DK motif. The role of the lysine residue in the DK motif is to control of the amino acid preference at the X position of the sequon via electrostatic interactions. The replacement of the lysine by arginine in the DK motif of yeast STT3 resulted in a lethal phenotype (21). This indicates that a simple mechanism based on electrostatic interactions is not sufficient to describe the function of the DK motif. Further investigations are necessary to clarify the precise role of the DK motif.
FIGURE 6.
Schematic model of the catalytic site of the OST enzyme and the presumed functions of the catalytic motifs. The residual OST activities of the alanine mutants are color-coded in the amino acid sequences. Three interactions are assumed to occur, at least transiently, during the oligosaccharyltransfer reaction. The present study suggests that the amino acid residue at the X position of the Asn-X-Thr sequon is located in close proximity to the lysine residue in the DK motif (i), that the highly conserved WWDYG is considered to be a nucleophilic region and would interact with the asparagine and threonine residues of the acceptor peptides (ii), and that the acidic residues in the DXD motif and Asp-167 are predicted to interact with the pyrophosphate group of LLO by binding to a divalent metal ion (M2+) (iii).
Possibility of Customizing OST
The mutations at residue 574 substantially reduced the OST activity when the optimized peptide sequence containing the Asn-Val-Thr sequon was used as a peptide substrate (Fig. 5A). We measured the OST activity using a new peptide substrate with the Asn-Arg-Thr sequon (Fig. 5B). Four mutants displayed higher activity than the wild type. This exemplifies the potential of a single mutation in the AglB protein to optimize its activity toward a particular target N-glycosylation sequon. For practical applications, the present study provides a novel strategy to overcome the macroheterogeneity problem of recombinant glycoproteins.
The eukaryotic STT3 proteins contain the DK motif, and thus the lysine residue in the motif is an obvious candidate for mutation. Recently, an innovative glycoprotein production system using the Campylobacter N-glycosylation machinery was reported (32). The key component of the machinery is Campylobacter PglB. The PglB protein possesses the MI motif in place of the DK motif (27). Mutations in the MI motif would affect the amino acid preference at the X position.
The common tendency of the changes in amino acid preference among the seven Lys-574 mutants of the P. furiosus AglB (Figs. 3C and 4) may preclude the flexible design of mutants targeted to a particular sequon with a variety of amino acid residues at the X position. We suggest that combinatorial mutation screening, based on the three signature sites in the DK/DM/MI motifs, may generate an optimized OST mutant for a particular substrate sequence. In fact, the alanine mutation of the third signature position of the DK motif, I578A, had a small effect on the amino acid preference at the X position (supplemental Fig. S3).
This work was supported by Grant-in-aid for Scientific Research on Innovative Areas 21121003, the Targeted Proteins Research Program (TPRP) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan, and Research Grant 090036 from the Mizutani Foundation for Glycoscience.

The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1–S4, experimental procedures, and results.
- OST
 - oligosaccharyltransferase
 - Agl
 - archaeal glycosylation
 - LLO
 - lipid-linked oligosaccharide
 - Pgl
 - protein glycosylation
 - STT
 - staurosporine and temperature sensitivity
 - TAMRA
 - carboxytetramethylrhodamine.
 
REFERENCES
- 1. Yan A., Lennarz W. J. (2005) J. Biol. Chem. 280, 3121–3124 [DOI] [PubMed] [Google Scholar]
 - 2. Knauer R., Lehle L. (1999) Biochim. Biophys. Acta 1426, 259–273 [DOI] [PubMed] [Google Scholar]
 - 3. Burda P., Aebi M. (1999) Biochim. Biophys. Acta 1426, 239–257 [DOI] [PubMed] [Google Scholar]
 - 4. Abu-Qarn M., Eichler J., Sharon N. (2008) Curr. Opin. Struct. Biol. 18, 544–550 [DOI] [PubMed] [Google Scholar]
 - 5. Gavel Y., von Heijne G. (1990) Protein Eng. 3, 433–442 [DOI] [PMC free article] [PubMed] [Google Scholar]
 - 6. Bause E., Hettkamp H. (1979) FEBS Lett. 108, 341–344 [DOI] [PubMed] [Google Scholar]
 - 7. Petrescu A. J., Milac A. L., Petrescu S. M., Dwek R. A., Wormald M. R. (2004) Glycobiology 14, 103–114 [DOI] [PubMed] [Google Scholar]
 - 8. Nita-Lazar M., Wacker M., Schegg B., Amber S., Aebi M. (2005) Glycobiology 15, 361–367 [DOI] [PubMed] [Google Scholar]
 - 9. Apweiler R., Hermjakob H., Sharon N. (1999) Biochim. Biophys. Acta 1473, 4–8 [DOI] [PubMed] [Google Scholar]
 - 10. Zielinska D. F., Gnad F., Wiśniewski J. R., Mann M. (2010) Cell 141, 897–907 [DOI] [PubMed] [Google Scholar]
 - 11. Jones J., Krag S. S., Betenbaugh M. J. (2005) Biochim. Biophys. Acta 1726, 121–137 [DOI] [PubMed] [Google Scholar]
 - 12. Wittwer A. J., Howard S. C., Carr L. S., Harakas N. K., Feder J., Parekh R. B., Rudd P. M., Dwek R. A., Rademacher T. W. (1989) Biochemistry 28, 7662–7669 [DOI] [PubMed] [Google Scholar]
 - 13. Picard V., Ersdal-Badju E., Bock S. C. (1995) Biochemistry 34, 8433–8440 [DOI] [PubMed] [Google Scholar]
 - 14. Igura M., Kohda D. (2011) Glycobiology, in press [DOI] [PubMed] [Google Scholar]
 - 15. Kasturi L., Chen H., Shakin-Eshleman S. H. (1997) Biochem. J. 323 (Pt 2), 415–419 [DOI] [PMC free article] [PubMed] [Google Scholar]
 - 16. Bañó-Polo M., Baldin F., Tamborero S., Marti-Renom M. A., Mingarro I. (2011) Protein Sci. 20, 179–186 [DOI] [PMC free article] [PubMed] [Google Scholar]
 - 17. Chen M. M., Glover K. J., Imperiali B. (2007) Biochemistry 46, 5579–5585 [DOI] [PubMed] [Google Scholar]
 - 18. Shakin-Eshleman S. H., Spitalnik S. L., Kasturi L. (1996) J. Biol. Chem. 271, 6363–6366 [DOI] [PubMed] [Google Scholar]
 - 19. Mellquist J. L., Kasturi L., Spitalnik S. L., Shakin-Eshleman S. H. (1998) Biochemistry 37, 6833–6837 [DOI] [PubMed] [Google Scholar]
 - 20. Kelleher D. J., Gilmore R. (2006) Glycobiology 16, 47R–62R [DOI] [PubMed] [Google Scholar]
 - 21. Igura M., Maita N., Kamishikiryo J., Yamada M., Obita T., Maenaka K., Kohda D. (2008) EMBO J. 27, 234–243 [DOI] [PMC free article] [PubMed] [Google Scholar]
 - 22. Feldman M. F., Wacker M., Hernandez M., Hitchen P. G., Marolda C. L., Kowarik M., Morris H. R., Dell A., Valvano M. A., Aebi M. (2005) Proc. Natl. Acad. Sci. U.S.A. 102, 3016–3021 [DOI] [PMC free article] [PubMed] [Google Scholar]
 - 23. Li L., Woodward R., Ding Y., Liu X. W., Yi W., Bhatt V. S., Chen M., Zhang L. W., Wang P. G. (2010) Biochem. Biophys. Res. Commun. 394, 1069–1074 [DOI] [PubMed] [Google Scholar]
 - 24. Kim H., von Heijne G., Nilsson I. (2005) J. Biol. Chem. 280, 20261–20267 [DOI] [PubMed] [Google Scholar]
 - 25. Yan Q., Lennarz W. J. (2002) J. Biol. Chem. 277, 47692–47700 [DOI] [PubMed] [Google Scholar]
 - 26. Wacker M., Linton D., Hitchen P. G., Nita-Lazar M., Haslam S. M., North S. J., Panico M., Morris H. R., Dell A., Wren B. W., Aebi M. (2002) Science 298, 1790–1793 [DOI] [PubMed] [Google Scholar]
 - 27. Maita N., Nyirenda J., Igura M., Kamishikiryo J., Kohda D. (2010) J. Biol. Chem. 285, 4941–4950 [DOI] [PMC free article] [PubMed] [Google Scholar]
 - 28. Hese K., Otto C., Routier F. H., Lehle L. (2009) Glycobiology 19, 160–171 [DOI] [PubMed] [Google Scholar]
 - 29. Glover K. J., Weerapana E., Numao S., Imperiali B. (2005) Chem. Biol. 12, 1311–1315 [DOI] [PMC free article] [PubMed] [Google Scholar]
 - 30. Kohda D., Yamada M., Igura M., Kamishikiryo J., Maenaka K. (2007) Glycobiology 17, 1175–1182 [DOI] [PubMed] [Google Scholar]
 - 31. Chavan M., Rekowicz M., Lennarz W. (2003) J. Biol. Chem. 278, 51441–51447 [DOI] [PubMed] [Google Scholar]
 - 32. Schwarz F., Huang W., Li C., Schulz B. L., Lizak C., Palumbo A., Numao S., Neri D., Aebi M., Wang L. X. (2010) Nat. Chem. Biol. 6, 264–266 [DOI] [PMC free article] [PubMed] [Google Scholar]
 






